Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery…
Travere Therapeutics And CSL Vifor Announce EMA Has Accepted For Review The Conditional Marketing Authorization Application For Sparsentan For The Treatment Of IgA Nephropathy
Travere Therapeutics, Inc. (NASDAQ:TVTX) and CSL Vifor today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgAN, a rare
SVB Leerink Maintains Outperform on Travere Therapeutics, Raises Price Target to $45
SVB Leerink analyst Joseph Schwartz maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $42 to $45.
FDA Says Travere’s Sparsentan Data Not Sufficient For Accelerated Approval In One Indication
Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare disease affecting the kidney filters.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Travere Therapeutics Provides Regulatory Updates On Its Development Programs
PDUFA target action date for NDA for sparsentan in IgAN on-track for November 17, 2022
Company to utilize traditional approval process for sparsentan in FSGS following completion of the pivotal Phase 3 DUPLEX
4 Analysts Have This to Say About Travere Therapeutics
Over the past 3 months, 4 analysts have published their opinion on Travere Therapeutics (NASDAQ:TVTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Piper Sandler Maintains Overweight on Travere Therapeutics, Raises Price Target to $41
Piper Sandler analyst Do Kim maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $40 to $41.